Appraising the costs of genomic testing for histology-independent technologies: an illustrative example for NTRK fusions
AffiliationCentre for Reviews and Dissemination, University of York, York, England, UK
MetadataShow full item record
AbstractObjectives: Histology-independent (HI) technologies are authorized for patients with advanced or metastatic cancer if they express a particular biomarker regardless of its position in the body. Although this represents an important advancement in cancer treatment, genomic testing to identify eligible individuals for HI technologies will require substantial investment and impact their cost-effectiveness. Estimating these costs is complicated by several issues, which affect not only the overall cost of testing but also the distribution of testing costs across tumor types. Methods: Key issues that should be considered when evaluating the cost of genomic testing to identify those eligible for HI technologies are discussed. These issues are explored in illustrative analyses where costs of genomic testing for NTRK fusions in England for recently approved HI technologies are estimated. Results: The prevalence of mutation, testing strategy adopted, and current testing provision affect the cost of identifying eligible patients. The illustrative analysis estimated the cost of RNA-based next-generation sequencing to identify 1 individual with an NTRK fusion ranged between £377 and £282 258. To improve cost-effectiveness, testing costs could be shared across multiple technologies. An estimated additional ∼4000 patients would need to be treated with other HI therapies for testing in patients with advanced or metastatic cancer to be cost-effective. Conclusions: The cost of testing to identify individuals eligible for HI technologies affect the drug's cost-effectiveness. The cost of testing across tumor types varies owing to heterogeneity in the mutation's prevalence and current testing provision. The cost-effectiveness of HI technologies may be improved if testing costs could be shared across multiple agents.
CitationBeresford L, Murphy P, Dias S, Claxton L, Walton M, Metcalf R, et al. Appraising the Costs of Genomic Testing for Histology-Independent Technologies: An Illustrative Example for NTRK Fusions. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2022 Jul;25(7):1133-40. PubMed PMID: 35779940. Epub 2022/07/03. eng.
- Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
- Authors: Murphy P, Glynn D, Dias S, Hodgson R, Claxton L, Beresford L, Cooper K, Tappenden P, Ennis K, Grosso A, Wright K, Cantrell A, Stevenson M, Palmer S
- Issue date: 2021 Dec
- NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
- Authors: Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, Jungbluth AA, Zehir A, Benayed R, Drilon A, Hyman DM, Ladanyi M, Sireci AN, Hechtman JF
- Issue date: 2020 Jan
- Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
- Authors: Koehne de González A, Mansukhani MM, Fernandes H, Hsiao SJ
- Issue date: 2022 Apr
- Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
- Authors: Doble B, John T, Thomas D, Fellowes A, Fox S, Lorgelly P
- Issue date: 2017 May
- A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children.
- Authors: Beale S, Sanderson D, Sanniti A, Dundar Y, Boland A
- Issue date: 2015 Jun